Enanta Pharmaceuticals

Upcoming events – mid-stage Nash data from NGM and Enanta near

Newly-listed NGM Biopharmaceuticals needs its Nash project to impress in phase II, while Enanta must show that it also has a foot in the door in the liver disease.

As Genfit deals and Conatus folds, Nash plays on

A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of clinical data.

February 19, 2019

Inventiva’s fibrosis flop hits Nash hopes

A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.

February 11, 2019

Intercept’s big Nash day draws near

Intercept Pharmaceuticals and the whole Nash field await Ocaliva’s pivotal readout.

September 21, 2016

Allergan’s second move spells showdown with Intercept and Gilead

January 29, 2016

Looking for a hep C price war? Merck just started it

January 26, 2016

Therapy focus – Merck and AbbVie still trail in Gilead’s hep C wake

November 02, 2015

Read my lips: no Humira biosimilars until 2022

May 20, 2015

J&J enlivens spent hep C franchise with Achillion deal

April 10, 2015

Good times roll in Q1 as mid and small cap winners outnumber losers

December 22, 2014

Viekira approval heralds start of hep C price war

Load More